Basware Corporation, stock exchange release, January 2, 2017 at 14:30 Update on personnel costs and 2016 reporting Basware launched a productivity programme on November 2, 2016 to simplify its operations and increase scalability, aimed at accelerating the growth of its cloud-based business and increasing productivity. The costs booked in 2016 related to personnel reductions being part of the productivity programme will amount to roughly EUR 5 million and will be included in "Adjustments to EBITDA" in Basware's fourth quarter and full year 2016 reporting. The targeted annual savings related to personnel of approximately EUR 7 to 8 million starting from 2018 are unchanged, in addition to other potential savings through the programme. Basware will publish its Financial Statements Bulletin for 2016 on Wednesday, February 1, 2017. For more information, please contact: Ben Selby, Head of Investor Relations, Basware Corporation Tel. +358 50 305 8077, ben.selby@basware.com Distribution: Nasdaq Helsinki Key media www.basware.com/investors About Basware: Basware (Nasdaq: BAS1V) is the global leader in providing networked purchase-to-pay solutions, e-invoicing and innovative financing services. Basware's commerce and financing network connects businesses in over 100 countries and territories around the globe. As the largest open business network in the world, Basware provides scale and reach for organizations of all sizes, enabling them to grow their business and unlock value across their operations by simplifying and streamlining financial processes. Small and large companies around the world achieve significant cost savings, more flexible payment terms, greater efficiencies and closer relationships with their suppliers. Find out more at www.basware.com/investors . Follow Basware on Twitter: @Basware, join the discussion on the Basware LinkedIn , Basware Facebook and Basware Blog and subscribe for the latest news.
Update on personnel costs and 2016 reporting Basware
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Merck & Co., Inc. Investors Urged to Take Action Now
Important Notice for Merck & Co., Inc. Investors Investors in Merck & Co., Inc. (MRK) are being encouraged to seek legal counsel as we approach a significant deadline related to a securities class action lawsuit. This timeline marks an important opportunity for purchasers of Merck's securities made between February 3, 2022, and February 3, 2025, to secure representation...
Continue Reading
Justice-Impacted Individuals Gaining Access to Education
Expanding Opportunities for Justice-Impacted Individuals In a significant initiative aimed at improving the lives of justice-impacted individuals, multiple states are coming together to enhance educational and workforce pathways. This collaborative effort is focused on providing necessary resources and opportunities for individuals who have faced incarceration, aiming to...
Continue Reading
Celebrating Excellence: 2025 Lifetime Achievement Award Recipients
Honoring Peter Murray and SawTeen See at the CTBUH 2025 Awards The Council on Tall Buildings and Urban Habitat (CTBUH) has recognized two remarkable figures in the field of architecture and structural engineering for their essential contributions to urban design. Peter Murray, co-founder of New London Architecture, and SawTeen See, a prominent structural engineer, are the...
Continue Reading
Northern Oil and Gas Expands Horizons with Acquisition Talks
Northern Oil and Gas Options for Strategic Growth Northern Oil and Gas is actively pursuing acquisition opportunities, specifically targeting Granite Ridge Resources. Based in Minneapolis, this ambitious company has shown intent to enhance its portfolio by considering Granite Ridge, a relatively smaller player in the oil industry, skilled in extracting resources from...
Continue Reading
Invivyd Announces Insights into VYD2311's Clinical Journey
Invivyd Hosts Webcast to Discuss the REVOLUTION Program Invivyd, Inc. (Nasdaq: IVVD) will present a live webcast detailing its innovative REVOLUTION clinical program. This event, aimed at both investors and the public, will showcase the company’s promising monoclonal antibody, VYD2311, which serves as a vaccine alternative for COVID-19 prevention. The Overview of...
Continue Reading